December 2004
Worldwide Biotech;Dec2004, Vol. 16 Issue 12, p2
Trade Publication
Reports on the U.S. patent allowance granted to the CRD5 drug developed by Ottawa, Ontario-based Liponex Inc. Therapeutic uses for the drug; Results of the clinical trials to test the safety of the drug; Discovery of the technology behind the drug.


Related Articles

  • Liponex Plummets As CRD5 Misses In Phase I/II Trial. Boggs, Jennifer // BioWorld Today;3/9/2007, Vol. 18 Issue 47, p1 

    The article reports on the performance of the shares of Liponex Inc. After the release of its Phase I/II data showing that its lead cholesterol drug, CRD5 failed to significantly increase high density lipoprotein (HDL) in dyslipidemic patients, Liponex lost three-fourths of its value. According...

  • Biosimilars Are Not Yet a Threat to Brand Patents. Serebrov, Mari // BioWorld Today;3/9/2011, Vol. 22 Issue 46, p1 

    The article examines the impact of a pay-for-delay patent settlement case in the U.S. Supreme Court on biologics. According to Bob Billings, interim executive director of the Generic Pharmaceutical Association, the regulatory pathway of the Food and Drug Administration (FDA) for biosimilars will...

  • LIPONEX PROVIDES CLINICAL TRIAL UPDATE.  // Worldwide Biotech;Sep2006, Vol. 18 Issue 9, p2 

    The article presents an update on the preparations of biopharmaceutical company Liponex Inc. for Phase I/II clinical trial of its lead compound CRD5 for the treatment of dyslipidemia and heart disease. The bulk active pharmaceutical ingredient from contract manufacturer has been received by the...

  • New drugs for osteoporosis. Comparison of the costs and required returns with those of other drugs intended for long-term use. Edwards, M. // PharmacoEconomics;1999, Vol. 15 Issue 3, p269 

    Specific regulatory guidelines dictate that developing a new drug for osteoporosis will be significantly more expensive and take at least 2 years longer in comparison with other long-term therapies developed using the International Committee on Harmonisation (ICH) general guidelines. Assuming...

  • Saturable Active Tubular Reabsorption in the Renal Clearance of Mesalazine in Human Volunteers. Vree, T.B.; Dammers, E.; Exler, P.S.; Sörgel, F.; Maes, R.A.A. // Clinical Drug Investigation;2000, Vol. 20 Issue 1, p35 

    Objective: To identify the reasons for the large variation in renal clearance of mesalazine. Design: Data were obtained from a randomised crossover bioequivalence study in 18 healthy volunteers. Methods: Participants received a single 1000mg oral dose of each of two different formulations of...

  • Expanding AIDS Drug Availability. Marwick, Charles // JAMA: Journal of the American Medical Association;9/8/89, Vol. 262 Issue 10, p1289 

    Cites the U.S. Food and Drug Administration's endorsement in principle of the concept of expanding the availability of drugs at the early stages of AIDS for treatment. Support for the initiative from AIDS activist groups and National Institute of Allergy and Infectious Diseases members; Issues...

  • United States Patent Granted for Irvingia.  // Life Extension;Aug2009, Vol. 15 Issue 8, p19 

    The article reports that Irvingia gabonensis, a plant extract, has been officially granted a patent by the U.S. Patent and Trademark Office. The extract is said to be helpful in weight loss and control lipids in humans. Clinical trials claims that it lowers blood pressure, increases high density...

  • Addiction Update.  // PharmaWatch: CNS;Sep2010, Vol. 9 Issue 9, p11 

    The article offers news briefs on addiction in the U.S. Nabi Pharmaceuticals has completed enrollment in the first Phase III clinical trial of investigation vaccine NicVAX for the treatment of nicotine addiction and prevention of smoking relapse. Pharmaceutical technology company Fuisz Pharma...

  • U.S. Patent Disclosures.  // BioWorld Today;8/30/2010, Vol. 21 Issue 167, p5 

    The article offers information on several U.S. patent disclosures, including a vaccine technology from Advaxis Inc., the Ligand Activated Therapy prodrug technology platform from KemPharm Inc. and processes for preparing amphoteric liposomes or SMARTICLES.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics